ENTRESTO® in systolic heart failure; Challenging the PARADIGM

DATE: THURSDAY 27TH APRIL 2017

TIME: 6:30PM FOR 7:00PM START, 9:00PM END

VENUE: THE PROVINCIAL HOTEL, 121 LYDIARD STREET, BALLARAT CENTRAL, VIC 3350

SPEAKER: DR. HENDRIK ZIMMET, CARDIOLOGIST, BALLARAT CARDIOLOGY

In this meeting, we will:

- Briefly examine the pathophysiology of HF including the role of neuro-hormonal systems and address the significant burden of HF.
- Explore the mode of action, clinical evidence and place in therapy for Entresto.
- Explore the evidence in a case based approach.

The meeting will provide the opportunity for discussion, allowing you to share your thoughts and perspectives and ask questions.

We look forward to seeing you at the meeting and hope that you find it to be stimulating and informative.

Program

6:30 PM       Registration
7:00 PM       Welcome, introduction and meeting objectives
7:10 PM       Meet Terry, burden of disease, pathophysiology and Entresto MOA
7:30 PM       Entresto clinical evidence
8:00 PM       Dinner
8:30 PM       Entresto place in therapy and practical use including case discussion
9:00 PM       Close

NOVARTIS

Entresto
sacubitril/valsartan
To register your attendance, please complete the following:

Return via fax (02) 8874 2319 or email to rep.assist@novartis.com or by contacting your Novartis Representative Cindie Sheard 0427 998 918 or Hamish Gordon 0428 599 372.

Name: ____________________________

Practice name: _____________________

Address: ___________________________

Phone number: _____________________

Email: _____________________________

Dietary requirements: _______________________

Please select the meeting you would like to attend

☐ 27th April 2017, 6.30pm at THE PROVINCIAL HOTEL, 121 LYDIARD STREET, CENTRAL, VIC 3350

We look forward to seeing you at the meeting and hope that you find it to be stimulating and informative.

COLLECTION STATEMENT: By providing your personal information to Novartis Pharmaceuticals Australia Pty Ltd or its related bodies corporate (Novartis), you consent to Novartis collecting, storing and using your personal information in accordance with the Novartis Privacy Policy. In particular, you consent to Novartis using your personal information to communicate with you about Novartis products and/or to support your use of those products. You also consent to Novartis using your personal information to (where applicable) invite you to, or arrange your participation in, activities managed by (or on behalf of) Novartis. You are not obliged to provide personal information. Novartis is committed to patient safety. In accordance with regulatory obligations, Novartis has a systematic process in place to collect, store and process reports of adverse events experienced by patients taking a Novartis product, when identified by a Novartis representative (or by a third party acting on behalf of Novartis). All information forwarded to the Novartis drug safety department is treated in accordance with local privacy laws and may be captured and processed in countries outside of the national territory, and shared with health authorities or other Pharmaceutical companies with whom Novartis has a license agreement, for the purpose of meeting the regulatory requirements for reporting safety information on Novartis products. Novartis drug safety department may contact the patient’s healthcare professional in order to collect further information on the adverse event. You are not obliged to provide personal information. However, if you do not provide information you may not, for example, be able to participate fully in activities managed by us. You have the right to access, update or correct your personal information and/or decline to receive communications from Novartis.

To find out how, please refer to our Privacy Policy at https://www.novartis.com.au/privacy-policy or contact our Privacy Officer at Novartis Australia, 54 Waterloo Road Macquarie Park NSW 2113. Phone: 02 9805 3555 Email: privacy.au@novartis.com

NOTE: In line with the Medicines Australia Code of Conduct, hospitality, travel or other expenses of any guest, family, or travelling companion will not be paid for or subsidised by Novartis. Attendees are responsible for obtaining approval to receive and/or disclose hospitality as required by their employer or professional association.

Novartis Pharmaceuticals Pty Limited. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. For medical enquiries please contact 1800 671 203 (phone) or modinfo.phaunc@novartis.com (email). ENV0150. NOV4670A. AU-0563 Prepared Feb 2017. AU-1119